FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365517017> ?p ?o ?g. }

• W4365517017 endingPage "CT060" @default.
• W4365517017 startingPage "CT060" @default.
• W4365517017 abstract "Abstract Background: H3 K27M-mutant diffuse midline glioma is a universally fatal malignancy primarily affecting children and young adults. While radiotherapy (RT) provides transient benefit, no effective systemic therapy is currently available and current standard of care is RT followed by monitoring. Dordaviprone (ONC201), a first-in-class imipridone, is an oral, blood-brain barrier penetrating, selective small molecule antagonist of dopamine receptor D2/3 (DRD2) and agonist of the mitochondrial protease ClpP. An integrated pooled analysis of five open-label trials previously demonstrated efficacy in dordaviprone-treated patients with recurrent disease. This phase 3 trial will be the first randomized, controlled study evaluating dordaviprone in patients with H3 K27M-mutant disease. Methods: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international Phase 3 study of dordaviprone in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy will be randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on two consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS) in all participants; PFS will be assessed by response assessment in neuro-oncology-high grade glioma by blind independent central review. Other objectives include assessments of safety, additional efficacy endpoints, clinical benefit, quality of life, pharmacokinetics, biomarkers, and healthcare resource utilization. Eligible patients will have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility will not be restricted based on age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in the United States, with additional sites to be open internationally in 2023. Citation Format: Isabel Arrillaga-Romany, Andrew Lassman, Susan L. McGovern, Sabine Mueller, Louis B. Nabors, Martin van den Bent, Michael Vogelbaum, Joshua E. Allen, Allen S. Melemed, Rohinton S. Tarapore, Dewen Yang, Patrick Wen, Timothy Cloughsey. ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT060." @default.
• W4365517017 created "2023-04-15" @default.
• W4365517017 creator A5000148424 @default.
• W4365517017 creator A5008547275 @default.
• W4365517017 creator A5009325014 @default.
• W4365517017 creator A5017360357 @default.
• W4365517017 creator A5021656597 @default.
• W4365517017 creator A5024616176 @default.
• W4365517017 creator A5039448543 @default.
• W4365517017 creator A5045679809 @default.
• W4365517017 creator A5057147234 @default.
• W4365517017 creator A5057541817 @default.
• W4365517017 creator A5084156179 @default.
• W4365517017 creator A5086283695 @default.
• W4365517017 creator A5088834594 @default.
• W4365517017 date "2023-04-14" @default.
• W4365517017 modified "2023-10-16" @default.
• W4365517017 title "Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma" @default.
• W4365517017 doi "https://doi.org/10.1158/1538-7445.am2023-ct060" @default.
• W4365517017 hasPublicationYear "2023" @default.
• W4365517017 type Work @default.
• W4365517017 citedByCount "0" @default.
• W4365517017 crossrefType "journal-article" @default.
• W4365517017 hasAuthorship W4365517017A5000148424 @default.
• W4365517017 hasAuthorship W4365517017A5008547275 @default.
• W4365517017 hasAuthorship W4365517017A5009325014 @default.
• W4365517017 hasAuthorship W4365517017A5017360357 @default.
• W4365517017 hasAuthorship W4365517017A5021656597 @default.
• W4365517017 hasAuthorship W4365517017A5024616176 @default.
• W4365517017 hasAuthorship W4365517017A5039448543 @default.
• W4365517017 hasAuthorship W4365517017A5045679809 @default.
• W4365517017 hasAuthorship W4365517017A5057147234 @default.
• W4365517017 hasAuthorship W4365517017A5057541817 @default.
• W4365517017 hasAuthorship W4365517017A5084156179 @default.
• W4365517017 hasAuthorship W4365517017A5086283695 @default.
• W4365517017 hasAuthorship W4365517017A5088834594 @default.
• W4365517017 hasConcept C126322002 @default.
• W4365517017 hasConcept C141341695 @default.
• W4365517017 hasConcept C142724271 @default.
• W4365517017 hasConcept C143998085 @default.
• W4365517017 hasConcept C168563851 @default.
• W4365517017 hasConcept C204787440 @default.
• W4365517017 hasConcept C27081682 @default.
• W4365517017 hasConcept C2778227246 @default.
• W4365517017 hasConcept C31760486 @default.
• W4365517017 hasConcept C502942594 @default.
• W4365517017 hasConcept C509974204 @default.
• W4365517017 hasConcept C535046627 @default.
• W4365517017 hasConcept C71924100 @default.
• W4365517017 hasConceptScore W4365517017C126322002 @default.
• W4365517017 hasConceptScore W4365517017C141341695 @default.
• W4365517017 hasConceptScore W4365517017C142724271 @default.
• W4365517017 hasConceptScore W4365517017C143998085 @default.
• W4365517017 hasConceptScore W4365517017C168563851 @default.
• W4365517017 hasConceptScore W4365517017C204787440 @default.
• W4365517017 hasConceptScore W4365517017C27081682 @default.
• W4365517017 hasConceptScore W4365517017C2778227246 @default.
• W4365517017 hasConceptScore W4365517017C31760486 @default.
• W4365517017 hasConceptScore W4365517017C502942594 @default.
• W4365517017 hasConceptScore W4365517017C509974204 @default.
• W4365517017 hasConceptScore W4365517017C535046627 @default.
• W4365517017 hasConceptScore W4365517017C71924100 @default.
• W4365517017 hasIssue "8_Supplement" @default.
• W4365517017 hasLocation W43655170171 @default.
• W4365517017 hasOpenAccess W4365517017 @default.
• W4365517017 hasPrimaryLocation W43655170171 @default.
• W4365517017 hasRelatedWork W1569073856 @default.
• W4365517017 hasRelatedWork W2094819424 @default.
• W4365517017 hasRelatedWork W2130626169 @default.
• W4365517017 hasRelatedWork W2624952492 @default.
• W4365517017 hasRelatedWork W2753890414 @default.
• W4365517017 hasRelatedWork W2959603226 @default.
• W4365517017 hasRelatedWork W3089163820 @default.
• W4365517017 hasRelatedWork W3200401126 @default.
• W4365517017 hasRelatedWork W4221026952 @default.
• W4365517017 hasRelatedWork W4282918911 @default.
• W4365517017 hasVolume "83" @default.
• W4365517017 isParatext "false" @default.
• W4365517017 isRetracted "false" @default.
• W4365517017 workType "article" @default.